EcoDrugPlus


Trade Names	PROHANCE PROHANCE MULTIPACK
Synonyms	Gadoteridol NSC-760055 Prohance Prohance multipack SQ 32,692 SQ-32692
Status
Molecule Category	Free-form
ATC	V08CA04
UNII	0199MV609F

Trade Names

PROHANCE

PROHANCE MULTIPACK

Synonyms

Gadoteridol

NSC-760055

Prohance

Prohance multipack

SQ 32,692

SQ-32692

Status

Molecule Category

Free-form

ATC

V08CA04

UNII

0199MV609F


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C17H29GdN4O7
Molecular Weight	558.69
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C17H29GdN4O7

Molecular Weight

558.69

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Mechanism of Action	Action	Reference
Diagnostic agent	None	DailyMed

Mechanism of Action

Action

Reference

Diagnostic agent

None

DailyMed

Resources	Reference
ChEMBL	CHEMBL1200593
FDA SRS	0199MV609F
PubChem	60714

Resources

Reference

ChEMBL

CHEMBL1200593

FDA SRS

0199MV609F

PubChem

60714


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

GADOTERIDOL

Physicochemical Descriptors

Bioactivity

Cross References